Myriad Genetics (NASDAQ:MYGN – Get Free Report) is set to announce its earnings results after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of ($0.01) per share for the quarter. Myriad Genetics has set its FY24 guidance at $0.00 to $0.05 EPS.
Myriad Genetics (NASDAQ:MYGN – Get Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.09. The firm had revenue of $202.20 million during the quarter, compared to the consensus estimate of $193.51 million. Myriad Genetics had a negative net margin of 30.30% and a negative return on equity of 6.77%. The firm’s revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.28) earnings per share. On average, analysts expect Myriad Genetics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Myriad Genetics Stock Performance
NASDAQ:MYGN traded down $0.08 during mid-day trading on Wednesday, reaching $27.73. The stock had a trading volume of 72,771 shares, compared to its average volume of 719,741. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.82 and a current ratio of 1.99. The firm has a market capitalization of $2.51 billion, a price-to-earnings ratio of -9.86 and a beta of 1.95. Myriad Genetics has a twelve month low of $13.82 and a twelve month high of $28.90. The business has a 50 day simple moving average of $24.67 and a 200 day simple moving average of $22.66.
Insider Activity at Myriad Genetics
Analysts Set New Price Targets
A number of equities research analysts recently commented on MYGN shares. SVB Leerink upgraded shares of Myriad Genetics from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $25.00 to $35.00 in a research report on Wednesday, May 8th. Jefferies Financial Group reaffirmed an “underperform” rating and issued a $20.00 target price (down from $25.00) on shares of Myriad Genetics in a report on Monday, June 3rd. Leerink Partnrs raised shares of Myriad Genetics from a “market perform” rating to an “outperform” rating in a research note on Wednesday, May 8th. Scotiabank started coverage on shares of Myriad Genetics in a report on Thursday, June 27th. They issued a “sector outperform” rating and a $29.00 price objective on the stock. Finally, Piper Sandler boosted their price objective on shares of Myriad Genetics from $23.00 to $28.00 and gave the stock a “neutral” rating in a report on Monday, May 13th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $25.33.
View Our Latest Stock Report on MYGN
About Myriad Genetics
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Featured Articles
- Five stocks we like better than Myriad Genetics
- Investing in Travel Stocks Benefits
- Joby Aviation Stock: The Case for Upside Just Got Stronger
- How is Compound Interest Calculated?
- Conviction Firms for Microsoft’s Double-Digit Stock Upside
- What Are the U.K. Market Holidays? How to Invest and Trade
- 5 Aggressive Growth Stocks for Long-Term Investors
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.